RE: ODX backed the wrong horse20 Jun 2023 23:04
Re USa:
2020:
Our strategy to address the US market has suffered a setback following one of our partners running into financial difficulties and we have now terminated its distribution agreement. As a result of this, we are now assessing different options to grow our revenues in this key market and expect to commence implementing this revised strategy towards the end of calendar year 2020.
2019:
We are also exploring how best to grow the US market, in light of and in full compliance with any regulatory requirements there.
2018:
Our US strategy was delayed because of a key partner's internal difficulties and, along with increased competition in our mature markets, resulted in a 6% decline on the prior year. We believe that this was a short-term issue and expect to return to the growth in our Food intolerance business that we have previously enjoyed. This will be driven primarily in the US as we work with our strategic partners to capitalise on the significant market opportunity. In addition, we are looking at a digital strategy to provide a better level of service for the end consumer.
The above excludes the announcements in the various raises/dilutions they have had to have over the years to stay afloat. Some of these mentioned specifically the US market development.
They know why they haven't broken the US.